They showed distinct expression WH-4-023 in vitro of V
gamma 9, V delta 2 transcripts and were positive for TCR gamma, but negative for TCR beta by immuno-histochemistry. Targeted inhibition of two oncogenic pathways (AURKA and NOTCH-1) by small-molecular inhibitors induced significant growth arrest in NK-cell lines, thus providing a rationale for clinical trials of these inhibitors in NK-cell malignancies. Leukemia (2011) 25, 348-358; doi:10.1038/leu.2010.255; published online 5 November 2010″
“Introduction: The cyclotron-based (100)Mo(p,2)(99m)Tc transformation has been proposed as a viable alternative to the reactor based (235)U(n,f)(99)Mo ->(99m)Tc strategy for production of (99m)Tc. Despite efforts to theoretically model the amount of ground-state (99g)Tc present at end of bombardment for the (p,2n) reaction, experimental validation has yet to be performed. The co-production of (998)Tc may have important implications in both the subsequent radiopharmaceutical chemistry and patient dosimetry upon injection.
Methods: To determine the extent of (99g)Tc co-production, we have experimentally measured the (100)Mo(p,x)(99)Mo, (99m)Tc, and (99g)Tc excitation functions in the 8-18 MeV range using a combination of natural abundance and 97.42% enriched (100)Mo foils along with gamma-ray spectrometry and ICP-MS. Although
the excitation functions for production of (99)Mo and (99m)Tc have been presented previously CDK inhibitor in the literature, to the best of our knowledge, this work presents the first experimental evaluation of the (100)Mo(p,2n)(99g)Tc excitation function.
Results: From the experimental cross-section measurements, the (99m)Tc production yields and (99m)Tc/(99m+g)Tc nuclei ratio were calculated for various thick target irradiation conditions. Results suggest that TBq quantities of (99m)Tc can be achieved with a (99m)Tc/(99m+g)Tc nuclei ratio that is on par with the current (99)Mo/(99m)Tc generator over standard eluted at a 24-h frequency.
Conclusion:
These findings suggest that the cyclotron production of (99m)Tc may be a feasible alternative to the current reactor-based production strategy. (C) 2011 Elsevier Inc. All rights reserved.”
“Introduction: The low-energy beta(-) emitter Tb-161 is very similar to Lu-177 with respect to half-life, beta energy and chemical properties. However, Tb-161 also emits a significant amount of conversion and Auger electrons. Greater therapeutic effect can therefore be expected in comparison to Lu-177. It also emits low-energy photons that are useful for gamma camera imaging.
Methods: The Gd-160(n,gamma)Gd-161 -> Tb-161 production route was used to produce Tb-161 by neutron irradiation of massive Gd-160 targets (up to 40 mg) in nuclear reactors. A semiautomated procedure based on cation exchange chromatography was developed and applied to isolate no carrier added (n.c.a.